489 documents

Read All
18:30 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De...
Read More
23:06 , Nov 27, 2018 |  BC Extra  |  Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De La Rosa...
Read More
15:21 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
Read More
15:21 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
Read More
20:49 , Sep 29, 2017 |  BC Extra  |  Clinical News

Merck discontinues HCV candidates

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
Read More
05:08 , Mar 3, 2017 |  BC Week In Review  |  Company News

Merck uprifosbuvir news

In an SEC filing, Merck said it would record a pretax impairment charge of $2.9 billion for HCV candidate uprifosbuvir ( MK-3862 ) based on "recent changes to the product profile, as well as changes...
Read More
23:54 , Feb 24, 2017 |  BC Extra  |  Company News

Merck takes haircut on Idenix asset

A shifting HCV market and pricing pressure caused Merck & Co. Inc. (NYSE:MRK) to dramatically reduce its expectations for uprifosbuvir (MK-3862), which the pharma gained in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc. in...
Read More
20:30 , Dec 16, 2016 |  BC Week In Review  |  Company News

Gilead, Merck infectious news

A federal jury ordered Gilead to pay Merck $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on a 10% royalty rate for Gilead's U.S....
Read More
00:16 , Dec 16, 2016 |  BC Extra  |  Company News

Jury awards Merck $2.5B in Gilead patent dispute

A federal jury ordered Gilead Sciences Inc. (NASDAQ:GILD) to pay Merck & Co. Inc. (NYSE:MRK) $2.5 billion in damages in an HCV patent infringement lawsuit. According to the jury's verdict, the damages are based on...
Read More
00:57 , Oct 21, 2015 |  BC Extra  |  Clinical News

Eight-week data for Merck's triple HCV combo

An abstract released ahead of next month's American Association for the Study of Liver Diseases (AASLD) meeting describes Phase II findings across multiple HCV genotypes produced by eight weeks of treatment with a once-daily regimen...
Read More